目的:报告原发性开角型青光眼(POAG)和玻璃体视网膜疾病患者的疗效和安全性。接受了ParsPlana玻璃体切除术(PPV)和ab-internoXENgel45(Abbvie)植入的患者。方法:这是一个回顾性的,观察,在佛罗伦萨“Careggi医院”眼科诊所接受ParsPlana玻璃体切除术和XENgel45支架植入术的五名患者的病例系列。最佳矫正视力(BCVA)评估,使用Goldmann压平眼压计(GAT)测量眼内压(IOP),几种青光眼药物在基线和基线时进行了评估,三,六,手术后12个月.术后1年内记录并发症。结果:5例患者共5只眼。眼压从术前平均21,2±3,3mmHg下降到随访期结束时(第12个月)的14,6±1,1mmHg,平均减少58%。一名患者需要进行针刺手术(20%)。没有人需要重新干预。我们没有记录任何低眼压病例(IOP<6.5mmHg),低眼压黄斑病变和脉络膜脱离。术后抗青光眼分子的数量平均为0,2±0,4。结论:我们的结果表明,对于患有视觉上明显的玻璃体视网膜疾病和POAG的患者,联合使用ParsPlana玻璃体切除术和XEN凝胶支架45植入是安全有效的。缩写:AC=前房,BCVA=最佳矫正视力,ERM=视网膜前膜,FTMH=全厚度黄斑孔,FU=氟尿嘧啶,GAT=戈德曼压平眼压计,眼压=眼内压,MIGS=微创青光眼手术,MMC=丝裂霉素C,NVG=新生血管性青光眼,OCT=光学相干断层扫描,POAG=原发性开角型青光眼,PPV=ParsPlana玻璃体切除术,SD=标准偏差,TB=小梁切除术,VF=视野,VMI=玻璃体关节界面,VMA=玻璃体黄斑粘连,VMT=玻璃体黄斑牵引。
Purpose: To report outcomes in terms of efficacy and safety of patients affected with Primary Open Angle Glaucoma (POAG) and Vitreoretinal Disease, who have undergone Pars Plana Vitrectomy (PPV) and ab-interno XEN gel 45 (Abbvie) implantations. Methods: This is a retrospective, observational, case series on five patients who underwent combined Pars Plana Vitrectomy and XEN gel Stent 45 implantation at \"Careggi Hospital\" Eye Clinic of Florence. Best-corrected visual acuity (BCVA) evaluation, intraocular pressure (IOP) measurements with Goldmann applanation tonometer (GAT), and several glaucoma medications were evaluated at the baseline and at one, three, six, and twelve months after surgery. Complications were recorded up to 1 year after surgery. Results: 5 eyes in five patients were enrolled. IOP dropped from an average of 21,2 ± 3,3 mmHg preoperatively to 14,6 ± 1,1 mmHg at the end of the follow-up period (month 12), with a mean percentage reduction of 58%. One patient needed a needling procedure (20%). None needed reintervention. We did not register any case of hypotony (IOP < 6,5 mmHg), hypotony maculopathy and choroidal detachment. The postoperative number of anti-glaucomatous molecules was on average 0,2 ± 0,4. Conclusion: Our results suggested that combined Pars Plana Vitrectomy and XEN gel stent 45 implantation is safe and effective for patients affected by visually significant vitreoretinal diseases and POAG. Abbreviations: AC = anterior chamber, BCVA = Best-corrected visual acuity,
ERM = epiretinal membrane, FTMH = full-thickness macular holes, FU = fluorouracil, GAT = Goldmann applanation tonometer, IOP = intraocular pressure, MIGS = minimally invasive glaucoma surgery, MMC = mitomycin C, NVG = neovascular glaucoma, OCT = optical coherence tomography, POAG = Primary Open Angle Glaucoma, PPV = Pars Plana Vitrectomy, SD = standard deviation, TB = Trabeculectomy, VF = visual field, VMI = Vitreomacular Interface, VMA = vitreomacular adhesion, VMT = vitreomacular traction.